FLT3 and acute myeloid leukemia: About 25% of AML patients carried FLT3-ITD that predicts poor outcome especially when it is located in the tyrosine kinase domain.20 Several tyrosine kinase inhibitors are currently under investigation since FLT3 could be a meaningful, actionable therapeutic target AML.21 In light of this, detection of MRD by monitoring this marker would be useful to measure the anti-leukemic activity of FLT3 inhibitors.